

Clinical trials of new drug under development for acute heart failure in all type of patients

TrialResults-center www.trialresultscenter.org

1 vasopressin receptor antagonist

| Trial | Treatments | Patients | Trials design and methods |
|--|------------|----------|---------------------------|
| Lixivaptan vs BALANCE <i>ongoing</i> [NCT00578695] n=NA follow-up: | - | - | |

References

BALANCE, 0:

2 Atrial natriuretic peptide

| Trial | Treatments | Patients | Trials design and methods |
|--|------------|----------|---------------------------|
| Ularitide vs TRUE-AHF <i>ongoing</i> [NCT01661634] n=NA follow-up: | - | - | |

References

TRUE-AHF, 0:

3 beta-blockers

| Trial | Treatments | Patients | Trials design and methods |
|--|------------|----------|---------------------------|
| beta-blockade continuation vs discontinuation | | | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|--|--|-----------------------------------|
| B-CONVINCED , 2009 [NCT00162565].] n=69/78 follow-up: | beta-blockade continuation versus discontinuation BB | acutely decompensated heart failure in patients with LVEF below 40% previously receiving stable beta-blocker therapy | Parallel groups open France |

References

B-CONVINCED, 2009:

Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, Jegou A, Bauer F, Trochu JN, Bouzamondo A, Tanguy ML, Lechat P B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalized for a decompensation episode. Eur Heart J 2009 Aug 30; [19717851]

4 calcium channel blocker

| Trial | Treatments | Patients | Trials design and methods |
|--|------------|----------|---------------------------|
| Clevidipine vs PRONTO <i>ongoing</i> [NCT00803634] n=NA follow-up: | - | - | |

References

PRONTO, 0:

5 endothelin receptor antagonist

| Trial | Treatments | Patients | Trials design and methods |
|--|------------|----------|---------------------------|
| tezosentan vs VERITAS 1 <i>ongoing</i> [NCT00525707] n=NA follow-up: | - | - | |
| VERITAS 2 <i>ongoing</i> [NCT00524433] n=NA follow-up: | - | - | |

References

VERITAS 1, 0:

6 human B-type natriuretic peptide

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---|
| nesiritide vs control | | | |
| NSGET (comparative trial) , 2000 n=203/102 follow-up: <5 days | nesiritide(0.015 and 0.030 microg/kg/min versus usual care | acutely decompensated heart failure requiring invasive monitoring | Parallel groups open US |
| nesiritide vs placebo | | | |
| ASCEND-HF , 2011 <i>unpublished</i> [NCT00475852] n=3496/3511 follow-up: 30 days | intravenous nesiritide for 24 hours to 7 days on top of standard therapy versus matching placebo | Patients hospitalized for heart failure (within 24 hours of hospitalization and institution of acute IV therapy for ADHF) | Parallel groups double-blind North America, Europe, Latin America, Asia-Pacific region |
| BNP-CARDS , 2007 [NCT00186329] n=39/36 follow-up: 7 days | nesiritide as a 0.01-g/kg/min infusion for 48 hours versus placebo | acute decompensated heart failure with moderate to severe renal insufficiency | Parallel groups Double blind US |
| FUSION 2 , 2008 [NCT00091520] n=911 follow-up: 12 weeks | nesiritide (2 g/kg bolus plus 0.01 g/kg-per-minute infusion for four to six hours) versus placebo | patients with ACC/AHA stage C/D heart failure with two recent heart-failure hospitalizations, an ejection fraction of less than 40% , and NYHA class 4 symptoms or NYHA class 3 symptoms with creatinine clearance less than 60 mL/min | Parallel groups double-blind |
| NSGET (efficacy trial) , 2000 n=85/42 follow-up: | nesiritide(0.015 and 0.030 microg/kg/min versus placebo | acutely decompensated heart failure requiring invasive monitoring | |
| PROACTION , 2003 n=127/123 follow-up: 30 days | nesiritidefor at least 12h versus placebo | patients presenting to the ED with acutely decompensated HF and dyspnea at rest or with minimal activity | Parallel groups double-blind USA |
| VMAC (intravenous nesiritide) , 2002 [NCT00083772] n=204/142 follow-up: | intravenous nesiritidefor 3 hours versus placebo | acutely decompensated heart failure requiring hospitalization | double-blind USA |
| nesiritide vs dobutamine | | | |
| PRECEDENT , 2002 [NCT00270400] n=NA follow-up: | nesiritide(0.015 or 0.03 microg/kg/min) versus Dobutamine (>or =5 microg/kg/min) | Symptomatic, Decompensated CHF | Parallel groups open |
| nesiritide vs nitroglycerin | | | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|--|--|---------------------------|
| VMAC (24h) , 2002 [NCT00083772] n=280/218 follow-up: | nesiritideinfusion for 24 hours versus nitroglycerin | acutely decompensated heart failure requiring hospitalization | |
| nesiritide vs standard care | | | |
| FUSION 1 , 2004 [NCT00270361] n=NA follow-up: 12 weeks | nesiritide 0.005 microg/kg/min or 0.010 microg/kg/min once weekly versus standard care | outpatient with co-morbid advanced heart failure and renal insufficiency | Parallel groups open |

References

NSGET (comparative trial), 2000:

ASCEND-HF, 2011:

BNP-CARDS, 2007:

FUSION 2, 2008:

NSGET (efficacy trial), 2000:

PROACTION, 2003:

VMAC (intravenous nesiritide), 2002:

PRECEDENT, 2002:

VMAC (24h), 2002:

FUSION 1, 2004:

7 levosimendan

| Trial | Treatments | Patients | Trials design and methods |
|--|---|---|---------------------------------|
| levosimendan vs placebo | | | |
| REVIVE-I , 2003 n=NA follow-up: | levosimendan 0.10.2 mg/kg/min versus placebo | patientst with HF andsymptoms at rest | Parallel groups |
| REVIVE II , 2013 [NCT00048425] n=299/301 follow-up: 5 days | Intravenous Levosimendan versus placebo | patients with decompensated chronic heart failure | Parallel groups double blind |
| RUSSLAN , 2002 n=NA follow-up: 14 days | Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) for 6h versus placebo | patients with left ventricular failure complicating acute myocardial infarction | Parallel groups double-blind |
| levosimendan vs dobutamine | | | |
| CASINO n=NA follow-up: | Levosimendan 16 mg/kg 0.2 mg/kg/min versus Dobutamine (10 mg/kg/min) and placebo | patients withdecompensatedlow-output HF | Parallel groups |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|--|---|--|
| LIDO , 2002 n=NA follow-up: 24h | Levosimendan versus Dobutamine | patients with low-output heart failure | Parallel groups double-blind |
| SURVIVE , 2007 [NCT00348504] n=664/663 follow-up: 180 days | Intravenous levosimendan versus intravenous dobutamine | patients hospitalized with acute decompensated heart failure who required inotropic support | Parallel groups double-blind 9 countries |

References

REVIVE-I, 2003:
REVIVE II, 2013:
RUSSLAN, 2002:
CASINO, 0:
LIDO, 2002:
SURVIVE, 2007:

8 positive inotropic agent

51

| Trial | Treatments | Patients | Trials design and methods |
|---|------------|----------|---------------------------|
| Istaroxime vs | | | |
| Debio 0614-202 <i>ongoing</i> [NCT00838253] n=NA follow-up: | - | - | |
| HORIZON-HF <i>ongoing</i> [NCT00616161] n=NA follow-up: | - | - | |
| CVie2015002 <i>ongoing</i> [NCT02617446] n=NA follow-up: | - | - | |

References

Debio 0614-202, 0:
HORIZON-HF, 0:
CVie2015002, 0:

9 relaxine

| Trial | Treatments | Patients | Trials design and methods |
|--|--|---|---------------------------------|
| serelaxin vs placebo | | | |
| RELAX-AHF , 2013 [NCT00520806] n=NA follow-up: | 48-h intravenous infusions of placebo or serelaxin (30 g/kg per day) within 16 h from presentation versus placebo (on top standard care) | patients admitted to hospital for acute heart failure | |
| Pre-RELAX-AHF , 2009 [NCT00520806] n=172/62 follow-up: | intravenous relaxin for 48 hours: 10g/kg daily, 30g/kg daily, 100g/kg daily, 250g/kg daily versus placebo | Patients hospitalized with acute heart failure | Parallel groups double blind |
| RELAX-AHF-2 <i>ongoing</i> [NCT01870778] n=NA follow-up: | - | Acute Heart Failure Patients | |

References

RELAX-AHF, 2013:

Pre-RELAX-AHF, 2009:

RELAX-AHF-2, :

10 selective adenosine-1 receptor antagonist

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---------------------------------|
| BAY1067197 vs placebo | | | |
| PARSIFAL <i>ongoing</i> [NCT02040233] n=NA follow-up: | - | patients with chronic heart failure | |
| rolofylline vs placebo | | | |
| PROTECT , 2010 [NCT00328692] n=NA follow-up: 3 days (60 days) | daily intravenous rolofylline (30 mg) for up to 3 days versus placebo | patients hospitalized for acute heart failure with impaired renal function | Parallel groups double-blind |
| REACH UP <i>ongoing</i> [NCT00443690] n=NA follow-up: | - | Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring Intravenous Therapy | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|----------------------------------|
| PROTECT-2 <i>ongoing</i> [NCT00354458] n=NA follow-up: | - | Patients Hospitalized With Acute HF and Volume Overload | |
| PROTECT-1 <i>ongoing</i> [NCT00328692] n=NA follow-up: | - | Patients Hospitalized With Acute HF and Volume Overload | |
| 7418-503 <i>ongoing</i> [NCT00729222] n=NA follow-up: | - | patients with heart failure and renal impairment | |
| 2007_s06 <i>ongoing</i> [NCT00652782] n=NA follow-up: | - | heart failure patients presenting with symptoms of volume overload requiring increased diuretic doses | |
| SLV320 vs placebo | | | |
| Reno-Defend 1 <i>ongoing</i> [NCT00744341] n=NA follow-up: | 2.5, 7.5, 15, and 30 mg/d SLV320 (1 hour intravenous infusions of 1.25, 3.75, 7.5, and 15 mg SLV320, every 12 hours for 3 days [a total of 6 doses] in addition to standard therapy) versus placebo | Subjects Hospitalized With Acute Decompensated Heart Failure and Renal Dysfunction | |
| S320.2.002 <i>ongoing</i> [NCT00160134] n=NA follow-up: | - | subjects with congestive heart failure requiring diuretic treatment | |
| tonapofylline vs placebo | | | |
| TRIDENT-1 <i>ongoing</i> [NCT00709865] n=NA follow-up: | - | Subjects With Acute Decompensated Heart Failure and Renal Insufficiency | |
| POSEIDON <i>ongoing</i> [NCT00745316] n=NA follow-up: | - | patients with heart failure and renal insufficiency | |

References

PARSiFAL, 0:
PROTECT, 2010:
REACH UP, 0:
PROTECT-2, 0:
PROTECT-1, 0:
7418-503, 0:
2007_s06, 0 :

Reno-Defend 1, 0:
 S320.2.002, 0:
 TRIDENT-1, 0:
 POSEIDON, 0:

11 ultrafiltration

| Trial | Treatments | Patients | Trials design and methods |
|--|------------|----------|---------------------------|
| vs | | | |
| UNLOAD n=NA follow-up: | - | - | |
| ultrafiltration vs | | | |
| AVOID HF [NCT01474200] n=NA follow-up: | - | - | |
| CARRESS-HF n=NA | - | - | |

References

UNLOAD, :
 AVOID HF, :
 CARRESS-HF, :

12 vasodilators

| Trial | Treatments | Patients | Trials design and methods |
|---|------------|----------|---------------------------|
| Cinaciguat vs | | | |
| COMPOSE EARLY <i>ongoing</i> [NCT01064037] n=NA follow-up: | - | - | |
| Cinaciguat vs | | | |
| COMPOSE 1 <i>ongoing</i> [NCT01065077] n=NA follow-up: | - | - | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|------------|----------|---------------------------|
| COMPOSE 2 <i>ongoing</i> [NCT01067859] n=NA follow-up: | - | - | |
| NCT00559650 <i>ongoing</i> [NCT00559650] n=NA follow-up: | - | - | |

References

COMPOSE EARLY, 0:
COMPOSE 1, 0:
COMPOSE 2, 0:
NCT00559650, 0:

13 vasodilators

| Trial | Treatments | Patients | Trials design and methods |
|--|------------|----------|---------------------------|
| ZP120 vs 05-025 <i>ongoing</i> [NCT00283361] n=NA follow-up: | - | - | |

References

05-025, 0:

14 vasopressin receptor antagonist

| Trial | Treatments | Patients | Trials design and methods |
|--|------------|----------|---------------------------|
| Conivaptan vs CONVERT-H <i>ongoing</i> [NCT00843986] n=NA follow-up: | - | - | |
| 087-CL-071 <i>ongoing</i> [NCT00057356] n=NA follow-up: | - | - | |

Pilder, SBPA Gemfibrozil, Apo-Gemfibrozil, Apo Gemfibrozil, ApoGemfibrozil, Ausgem, , heparin, Heparin, Unfractionated Heparin, Heparinic Acid, Liquaemin, Sodium Heparin, Heparin Sodium, alpha-Heparin, alpha Heparin, , hirudin, ibopamine, labetalol, Labetalol, Labetolol, Albetol, Apo-Labetalol, Apo Labetalol, ApoLabetalol, Dilevalol, Normodyne, Presolol, SCH-19927, SCH 19927, SCH19927, Trandate, AH-5158, AH 5158, AH5158, Labetalol Hydrochloride, , magnesium, nadroparin, Nadroparine, Fraxiparin, Fraxiparine, CY 216, CY-216, CY216, LMF CY-216, LMF CY 216, LMF CY216, , nicardipine, Nicardipine, Cardene SR, Dagan, Flusemide, Lecibril, Lincil, Loxen, Lucenfal, Nicardipine Hydrochloride, Nicardipine LA, Nicardipino Ratiopharm, Nicardipino Seid, Perdipine, Ridene, Y-93, Y 93, Y93, Cardene I.V., Cardene, Vasonase, Antagonil, , nicorandil, Nicorandil, 2-Nicotinamidoethyl Nitrate, 2 Nicotinamidoethyl Nitrate, 2-Nicotinamidethyl Nitrate, 2 Nicotinamidethyl Nitrate, SG-75, SG 75, SG75, Ikorel, Adancor, Dancor, , nifedipine, nifedipine, Nifedipine, Adalat, Bay-1040, Bay 1040, Bay1040, BAY-a-1040, BAY a 1040, BAYa1040, Procardia XL, Nifedipine-GTIS, Nifedipine GTIS, Corinfar, Korinfar, Fenigidin, Nifangin, Nifedipine Monohydrochloride, Procardia, Vascard, Cordipin, Cordipine, , nitroglycerin, Nitroglycerin, Glyceryl Trinitrate, Nitrolan, Nitrostat, Perlinganit, Susadrin, Sustac, Sustak, Sustonit, Transderm Nitro, Tridil, Trinitrin, Trinitrolong, Anginine, Dynamite, Gilustenon, Nitrangin, Nitro-Bid, Nitro Bid, NitroBid, Nitro-Dur, Nitro Dur, NitroDur, Nitrocard, Nitroderm, Nitroderm TTS, Nitroglyn, Nitrol, Nitrong, Nitrospan, , omapatrilat, omapatrilat, Vanlev, BMS 186716, BMS-186716, , omacor, Omacor, Lovaza, omega-3 ethyl ester 90, P-OM3 adjunct, , dalteparin, logiparin, Logiparin, LHN-1, , orlistat, orlistat, tetrahydrolipstatin, THLP, Alli, Xenical, , oxprenolol, pentoxifylline, Pentoxifylline, Oxpentifylline, BL-191, BL 191, BL191, Trental, Torental, Agapurin, Pentoxil, , perindopril, Perindopril, Pirindopril, Perstarium, S-9490, S 9490, S9490, S 9490-3, S 9490 3, S 94903, Perindopril Erbumine, , pindolol, picotamide, pioglitazone, Actos, practolol, Practolol, ICI-50172, ICI 50172, ICI50172, Dalzic, Eralzdin Practolol, , pravastatin, Pravastatin, Eptastatin, Liplat, RMS-431, RMS 431, RMS431, SQ-31000, SQ 31000, SQ31000, Vasten, Bristacol, CS-514, CS 514, CS514, Lipemol, Prareduct, Mevalotin, Pravachol, Elisor, Selektine, Pravacol, Pravasin, Lipostat, , prasugrel, prasugrel, CS 747, CS-747, LY 640315, LY640315, LY-640315, Effient, Efient, PCI, probucol, Probucol, DH-581, DH 581, DH581, Lorelco, Lurselle, Superlipid, Biphenabid, Panavir, , propanolol, Propranolol, Propanolol, Avlocardyl, AY-20694, AY 20694, AY20694, Betadren, Dexpropranolol, Inderal, Obsidan, Obzidan, Propranolol Hydrochloride, Rexigen, Anaprilin, Anapriline, Dociton, , propranolol, quinapril, quinidine, ramipril, Triatec, Altace, Delix, Ramace, Vesdil, Carasel, Acovil, Tritace, Zabien, ranolazine, renolazine, RS 43285-193, Ranexa, RS 43285, RS-43285, , rimonabant, rimonabant, SR141716, SR 141716, Acomplia, Zimulti, SR 141716A, SR141716A, SR-141716A, , risedronate, rivaroxaban, Xarelto, BAY 59-7939, , rosiglitazone, Avandia, rosuvastatin, Crestor, rt-PA, Tissue Plasminogen Activator, Tissue Activator D-44, Tissue Activator D 44, Tisokinase, Tissue-Type Plasminogen Activator, Tissue Type Plasminogen Activator, TTPA, T-Plasminogen Activator, T Plasminogen Activator, Alteplase, Activase, Actilyse, Lysatec rt-PA, Lysatec rt PA, Lysatec rtPA, , saruplase, saruplase, prourokinase (enzyme-activating), recombinant unglycosylated single-chain urokinase-type plasminogen activator, pro-urokinase, Rescupase, A-74187, , simvastatin, Zocor, sotalol, Darob, MJ-1999, MJ 1999, MJ1999, , streptokinase, sulfapyrazone, suloctidil, sulotroban, t-pa, telmisartan, telmisartan, Micardis, BIBR 277, BIBR-277, Pritor, , tenecteplase, tenecteplase, Metalyse, TNKase, terbogrel, ticlopidine, Ticlopidine, Ticlopidine Hydrochloride, Ticlodix, Ticlodon, 53-32C, 53 32C, 5332C, Ticlid, , timolol, Timolol, Timoptic, Timoptol, Timolol Hemihydrate, Timacar, Timolol Maleate, MK-950, MK 950, MK950, Optimol, Blocadren, , tinzaparin, tinzaparin, tinzaparin sodium, Innohep, tirofiban, tirofiban, tirofiban hydrochloride monohydrate, MK 383, MK-383, tirofiban hydrochloride, Aggrastat, Cahill May Roberts brand of tirofiban hydrochloride monohydrate, MSD brand of tirofiban hydrochloride monohydrate, Merck Frosst brand of tirofiban hydrochloride monohydrate, Merck Sharp and Dohme brand of tirofiban hydrochloride monohydrate, Agrastat, Merck brand of tirofiban hydrochloride monohydrate, L 700462, L-700462, , tolvaptan, tolvaptan, OPC 41061, OPC-41061, Samsca, , topiramate, topiramate, Topamax, Epitomax, McN 4853, McN-4853, , trandolapril, trandolapril, Odrik, Udrik, RU 44570, RU44570, RU-44570, Mavik, Gopten, triflusal, triflusal, Disgren, trimetazidine, Centrophne, Vastarel, Idaptan, Trimetazidine Irex, Vasartel, Trimetazidine Dihydrochloride, , urokinase, Urokinase-Type Plasminogen Activator, Urokinase Type Plasminogen Activator, U-Plasminogen Activator, U Plasminogen Activator, U-PA, Urinary Plasminogen Activator, Urokinase, Renokinase, Abbokinase, Kidney Plasminogen Activator, Single-Chain Urokinase-Type Plasminogen Activator, Single Chain Urokinase Type Plasminogen Activator, , valsartan, valsartan, Diovan, Tareg, KalpressMiten, Provas, Vals, walsartan, CGP 48933, Nisis, Aventis brand of valsartan, , verapamil, Verapamil, Iproveratril, Cordilox, Dexverapamil, Falicard, Izoptin, Isoptine, Isoptin, Lekoptin, Verapamil Hydrochloride, Calan, Finoptin, , vesnarinone, vesnarinone, OPC 8212, OPC-8212, , vitamin c, vitamin e, warfarin, xamoterol, Xamoterol, Corwin, ICI-118587, ICI 118587, ICI118587, Xamoterol Fumarate, Xamoterol Hemifumarate, Xamoterol Monohydrobromide, Xamoterol Monohydrochloride, Xamtol, Carwin, Xamoterol Maleate (2:1), , ximelagatran, ximelagatran, xi-melagatran, Exanta, H 376 95, H 376-95, , glipizide, Glucotrol, wafarin, Warfarin, Coumadine, Apo-Warfarin, Gen-Warfarin, Warfant, Coumadin, Marevan, Warfarin Potassium, Warfarin Sodium, Aldocumar, Tedicumar, , UFH, thiazid diuretic, sulodexide, reviparin, reviparin, reviparine, reviparin-sodium, reviparin sodium, LU 47311, LU-47311, Clivarin, Abbott

brand of reviparin-sodium, Clivarine, ICN brand of reviparin-sodium, , propafenone, Propafenone, Propamerck, Rythmol, Arythmol, Rytmonorm, Norfenon, Pintoform, Propafenon Minden, Rytmo-Puren, Rytmogenat, Baxarytmon, Cuxafenon, Fenoprain, Jutanorm, Nistaken, Prolecofen, , nateglinide, nateglinide, nate-glinide, senaglinide, IPCCPA, AY 4166, AY-4166, DJN 608, Starsis, Starlix, Novartis brand of nateglinide, A 4166, A-4166, Fastic, , nisoldipine, Bay K 5552, , metformin, Metformin, Dimethylguanylguanidine, Dimethylbiguanidine, Glucophage, , glyburide, Glyburide, Glybenclamide, Glibenclamide, Diabeta, Euglucon 5, Neogluconin, HB-419, HB 419, HB419, HB-420, HB 420, HB420, Maninil, Micronase, Daonil, Euglucon N, , 4-transhydroxy glyburide, , Glucovance, Glyburide-metformin, , eptifibatide, Integrilin, Integrelin, PTCA, reteplase, reteplase, Retavase, Rapilysin, betaxolol, Betaxolol, SL-75212, SL 75212, SL75212, Betoptic, Betoptima, Betaxolol, Oxodal, ALO-1401-02, ALO 1401 02, ALO140102, Betaxolol, atorvastatin, Lipitor, anistreplase, estrogen, thyroxine, policosanol, hydralazine-ISDN, isosorbide dinitrate, pactimibe, epoprostenol, torcetrapib, torcetrapib, CP 529414, CP529414, CP-529414, , catheter ablation, sirolimus eluting stent, CYPHER, , biolimus eluting stent, everolimus eluting stent, XIENCE V, Guidant XIENCE V, Abbott XIENCE V, XIENCE 5, zotarolimus eluting stent, Endeavour, Medtronic Endeavour, albiglutide, albiglutide, , ketanserin, liraglutide, liraglutide, victoza, nouveau, exenatide, exendin 4, exendin-4, Ex4 peptide, Byetta, AC 2993, AC 2993 LAR, , sitagliptin, sitagliptin, sitagliptin phosphate, Januvia, MK 0431, MK0431, MK-0431, , amlodipine, abciximab, acenocoumarol, Acenocoumarol, Nicoumalone, Acenocoumarin, Synthrome, Synthrom, Syncoumar, Syncumar, Sinkumar, Sintrom, Mini-Sintrom, Mini Sintrom, MiniSintrom, , alteplase, Tissue Plasminogen Activator, Tissue Activator D-44, Tissue Activator D 44, Tisokinase, Tissue-Type Plasminogen Activator, Tissue Type Plasminogen Activator, TTPA, T-Plasminogen Activator, T Plasminogen Activator, Alteplase, Activase, Actilyse, Lysatec rt-PA, Lysatec rt PA, Lysatec rtPA, , beta carotene, bepridil, Bepridil Monohydrochloride, Vascor, Bedapin, CERM-1978, CERM 1978, CERM1978, 1978-CERM, 1978 CERM, 1978CERM, Cordium, Unicordium, Bepadin, , clofibrate, Ethyl Chlorophenoxyisobutyrate, Atomid, Atomid S, Miskleron, Miskleron, Athromidin, , elinogrel, elinogrel, PRT 060128, PRT060128, PRT-060128, , nesiritide, Brain Natriuretic Peptide, BNP-32, BNP 32, Nesiritide, B-Type Natriuretic Peptide, BNP Gene Product, Type-B Natriuretic Peptide, Type B Natriuretic Peptide, Natriuretic Peptide Type-B, Natriuretic Peptide Type B, Natriuretic Factor-32, Natriuretic Factor 32, Brain Natriuretic Peptide-32, Brain Natriuretic Peptide 32, Natreacor, , phenindione, Phenindione, Phenylindanedione, Phenylene, Pindione, Fenilin, Dindevan, , repaglinide, repa-glinide, AG-EE 388 ZW, NovoNorm, GlucoNorm, Prandin, AG-EE 388, AG-EE 623 ZW, , ticagrelor, Brilique, Brilinta, AZD 6140, AZD6140, AZD-6140, zofenopril, zofenopril, Zofenil, Zofil, SQ 26900, SQ-26900, SQ 26991, SQ-26991, , SQ 26703, zofenopril-SH, zofenopril-SH cpd with arginine, , anacetrapib, MK 0859, MK0859, MK-0859, , atopaxar, betrixaban , PRT054021, , buflomedil, blufomedil, bufomedil, Buflor AbZ, AbZ brand of buflomedil hydrochloride, Buflor-POS, Ursapharm brand of buflomedil hydrochloride, Buflor-Puren, Alpharma brand of buflomedil hydrochloride, Buflorhexal, Hexal brand of buflomedil hydrochloride, Buflomedil Heumann, Heumann brand of buflomedil hydrochloride, buflomedil hydrochloride, Buflomedil Lindo, Lindopharm brand of buflomedil hydrochloride, buflomedil pyridoxal phosphate, Buflomedil Stada, Stadapharm brand of buflomedil hydrochloride, buflomedil von ct, ct-Arzneimittel brand of buflomedil hydrochloride, Buflomedil-ratiopharm, ratiopharm brand of buflomedil hydrochloride, Fonzylane, Lafon brand of buflomedil hydrochloride, LL 1656, Loftyl, Bufedil, Lofton, Abbott brand of buflomedil hydrochloride, Sinaxis, Hosbon brand of buflomedil hydrochloride, Buflor 1A Pharma, 1A brand of buflomedil hydrochloride, , folic acid, Folic Acid, Vitamin M, Pteroylglutamic Acid, Folate, Folvite, Folacin, , hydrochlorothiazide , Hydrochlorothiazide, HCTZ, Dichlothiazide, Dihydrochlorothiazide, HydroDIURIL, Oretic, Sectrazide, Esidrix, Esidrex, Hypothiazide, , inogatran, inogatran, N-(2-(2-(((3-((aminoiminomethyl)amino)propyl)amino)carbonyl)-1-piperidiny)-1-(cyclohexylmethyl)-2-oxo-ethyl)glycine, H 314-27, H314-27, H-314-27, , troglitazone, voglibose, voglibose, Basen, , trapidil, Trapidil, Trapymine, Rocornal, , desdiethyltrapidil, N-dediethyltrapidil, desdiethyl-trapidil, , Certoparin, certoparin, certoparin sodium, Mono-Embolex, Novartis brand of certoparin sodium, Alphaparin, Grifols brand of certoparin sodium, , glimepiride, glimepiride, glymepiride, HOE 490, HOE-490, Roname, Amaryl, Amarel, hydroxyglimepiride, hydroxy-glimepiride, , linagliptin, Linagliptin, Tradjenta, BI 1356, BI1356, BI-1356, , taspoglutide, taspoglutide, , mitiglinide, miti-glinide, KAD 1229, KAD-1229, , TAVI, transcatheter aortic valve implantation, , Sibutramine , sibutramine, Meridia, monodesmethylsibutramine, BTS 54 524, BTS-54524, BTS 54524, Reductil, di-desmethylsibutramine, didesmethylsibutramine, (R)-DDMS, sibutramine hydrochloride, , saxagliptin, saxagliptin, Onglyza, BMS 477118, BMS477118, BMS-477118, , divers, edoxaban, eplerenone, eplerenon, Inspra, fibroblast growth factor, aliskiren , CGP 060536B, CGP060536B, CGP-060536B, Tekturna, SPP100, , alogliptin, SYR 322, SYR322, SYR-322, , Azithromycin, benfluorex, benfluramate, benfluorex maleate, SE 780, 780 SE, JP 992, Mediator trade name of benfluorex hydrochloride, Bio-pharma brand of benfluorex hydrochloride, Modulator trade name of benfluorex hydrochloride, Servier brand of benfluorex hydrochloride, S 780, benfluorex hydrochloride, 1-(2-trifluoromethylphenyl)-2-(benzoyloxyethyl)aminopropane HCl, , bosentan, Coronary Artery Bypass Surgery, Coronary Artery Bypass, Coronary Artery Bypasses, Coronary Artery Bypass Surgery, Aortocoronary Bypass, Aortocoronary Bypasses, Coronary Artery Bypass Grafting, CABG, cangrelor, AR C69931MX, AR-C69931MX, , caval filter, carotid endarterectomy, Carotid Endarterectomy,

Carotid Endarterectomies, , carotid artery stenting, cilostazol, chlorthalidone, Chlortalidone, Phthalamudine, Chlorphthalidolone, Oxodoline, Thalitone, Hygroton, , dactinomycin eluting stent, defibrotide, disopyramide, dofetilide, dofetilide, 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane, 1-MSPMPE, Tikosyn, UK 68798, , docetaxel, docetaxol, Taxoltere metro, Taxotere, NSC 628503, RP 56976, RP-56976, Ebselen, ebselen, PZ 51, PZ-51, RP 60931, DR 3305, DR-3305, , Enoximone, Fenoximone, Perfan, MDL 19438, MDL-17043, MDL 17043, MDL17043, , enoximone sulfoxide, MDL 17043 sulfoxide, , Exercise Therapy, Exercise Therapy, Exercise Therapies, , Flosequinan, gene therapy, Gene Therapy, DNA Therapy, Somatic Gene Therapy, , ginko biloba, Ginkgo biloba, Ginkgo bilobas, Ginko, Ginkos, Ginkgo, Ginkgos, Gingko, Gingkos, Maidenhair Tree, Maidenhair Trees, Ginkgo biloba, Ginkgo bilobas, Ginkgophyta, Ginkgophytas, , lacidipine, Lacipil, Lacimen, Caldine, Motens, GR 43659X, GR-43659X, , molsidomine, mibefradil, lorcaserin, olmesartan, olmesartan medoxomil, CS 866, CS-866, Votum, Benicar, Olmetec, , nimodipine, Nimesulide, moricizine, otamixaban, pexelizumab, h5G1.1-scFv, pexelizumab, , Ambrisentan, amitriptyline, Azimilide, Bemiparin, Bupropion, Celecoxib, cilazapril, deltaparin, Dalteparin, Tedelparin, Kabi-2165, Kabi 2165, Kabi2165, Fragmin, Fragmine, Dalteparin Sodium, FR-860, FR 860, FR860, , Diazepam, Diclofenac, Efegatran, efegatran, Me-Phe-Pro-Arg-H, D-methylphenylalanyl-prolyl-arginal, GYKI 14766, GYKI-14766, LY 294468, LY-294468, efegatran sulfate, , Enlimomab, etofibrate, etofibrate, Lipo-Merz, Merz brand of etofibrate, Tricerol, Armstrong brand of etofibrate, etofibrate hydrochloride, , levosimendan, simendan, OR-1855, Simadax, dextrosimendan, OR 1259, OR-1259, , Milrinone, lixisenatide , ZP10A peptide, AVE 0010, AVE0010, AVE-0010, Lixisenatide, AQVE-10010, , primary angioplasty, primary ballon angioplasty, primary PTCA, vildagliptin, vildagliptin, (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile, NVP-LAF237, Galvus, , gliclazide, Gliclazide, Glyclazide, Gliklazid, Diamicron, S-1702, S 1702, S1702, S-852, S 852, S852, Diaglyk, Gen-Gliclazide, Gen Gliclazide, Glyade, Novo-Gliclazide, Novo Gliclazide, Diaikron, Diabrezide, , phentermine and topiramate, Qnexa, glimepiride, largine, vorapaxar, Zontivity, SCH 530348, SCH530348, SCH-530348, , nivolumab, MDX-1106, ONO-4538, BMS-936558, Opdivo, pembrolizumab, lambrolizumab, Keytruda, MK-3475, , ipilimumab, MDX-CTLA-4, Yervoy, DX 010, MDX010, MDX-010, , gefitinib, Iressa, ZD1839, ZD 1839, , paclitaxel, Anzatax, NSC-125973, NSC 125973, NSC125973, Taxol, Taxol A, Bris Taxol, Paxene, Praxel, 7-epi-Taxol, 7 epi Taxol, Onxol, everolimus, SDZ RAD, SDZ-RAD, 40-O-(2-hydroxyethyl)-rapamycin, RAD 001, RAD001, Afinitor, Certican, , pertuzumab, pertuzumab, Perjeta, Omnitarg, trastuzumab emtansine , ado-trastuzumab emtansine, trastuzumab-DM1, trastuzumab-DM1 conjugate, T-DM1 cpd, trastuzumab emtansine, huN901-DM1, Kadcyla, lapatinib , bevacizumab, Avastin, , gemcitabine, gemcitabine, dFdCyd, 2'-deoxy-2'-difluorocytidine, gemcitabine hydrochloride, LY 188011, LY-188011, Gemzar, , toremifene , Toremifene, Toremifene Citrate, Toremifene Citrate (1:1), Fareston, FC-1157a, FC 1157a, FC1157a, , capecitabine , Xeloda, , cisplatin , Cisplatin, cis-Diamminedichloroplatinum(II), Platinum Diamminodichloride, cis-Platinum, cis Platinum, Dichlorodiammineplatinum, cis-Diamminedichloroplatinum, cis Diamminedichloroplatinum, cis-Dichlorodiammineplatinum(II), NSC-119875, Platino, Platinol, Biocisplatinum, Platidiam, , fulvestrant , ICI 182780, ICI-182780, ZM 182780, ZM-182780, Faslodex, , palbociclib , palbociclib, Ibrance, PD 0332991, PD0332991, PD-0332991, anastrozole, anastrozole, anastrazole, ICI D1033, ZD-1033, Zeneca ZD 1033, ZD1033, Arimidex, letrozole, letrozole, Femara, Fmara, CGS 20267, CGS-20267, aminoglutethimide , Aminoglutethimide, Cytadren, Orimeten, formestane , formestane, 4-hydroxyandrostenedione, 4-OHA, Lentaron, CGP-32349, CGP 32 349, CGP 32349, , exemestane , exemestane, FCE 24304, FCE-24304, Aromasil, Aromasin, Aromasine, , fadrozole , Fadrozole, CGS-16949A, CGS 16949A, CGS16949A, Fadrozole Hydrochloride, Fadrozole Monohydrochloride, CGS 020286A, CGS020286A, CGS-020286A, FAD 286, FAD286, FAD-286, , tamoxifen, Tamoxifen, ICI-47699, ICI 47699, ICI47699, Nolvadex, Novaldex, Tamoxifen Citrate, Tomaxithen, Zitazonium, ICI-46474, ICI 46474, ICI46474, Soltamox, ixabepilone , ixabepilone, BMS247550, BMS-247550, BMS 247550, trastuzumab, Herceptin, temsirolimus , Torisel, CCI 779, CCI-779, , alirocumab, alirocumab, REGN727 monoclonal antibody, monoclonal antibody REGN727, SAR236553, Praluent, , evolocumab , AMG 145, evolocumab, AMG-145, Repatha, medroxyprogesterone , Medroxyprogesterone Acetate, Medroxyprogesterone 17-Acetate, Medroxyprogesterone 17 Acetate, Depo-Medroxyprogesterone Acetate, Depo Medroxyprogesterone Acetate, 6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate, 6 alpha Methyl 17alpha hydroxyprogesterone Acetate, Curretab, Cycrin, Depo-Provera, Depo Provera, DepoProvera, Farlutal, Perlutex, Provera, Veramix, Clinovir, Gestapuran, sorafenib, sorafenib, sorafenib N-oxide, 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methamide-4-methylbenzenesulfonate, BAY 545-9085, BAY-545-9085, sorafenib tosylate, BAY 43-9006, Nexavar, , entinostat , entinostat, SNDX-275, MS 27-275, MS-275, MS 275, eribulin, B 1939, B-1939, E 7389, E-7389, Halaven, NSC 707389, NSC707389, NSC-707389, B 1793, B-1793, ER-086526, ER086526, ER 086526, ER-86526, , nab-paclitaxel, Abraxane, vinorelbine , vinorelbine, 5'-nor-anhydrovinblastine, Navelbine, vinorelbine tartrate, KW 2307, KW-2307, , intensive blood pressure lowering strategies, intensive treatment, tighter control of blood pressure, low target blood pressure, strict blood pressure control, intensified blood-pressure control, cetuximab, IMC C225, IMC-C225, MAb C225, C225, Erbitux, , erlotinib, Tarceva, CP 358774, CP-358774, OSI-774, axitinib, Inlyta, AG 013736, AG013736, AG-013736, , dovitinib, TKI 258, TKI258,

TKI-258, dovitinib, CHIR 258, CHIR258, CHIR-258, , pazopanib, GW 786034B, GW786034B, GW-786034B, GW 780604, GW780604, GW-780604, Votrient, , sunitinib, Sutent, SU 11248, SU11248, SU-11248, SU011248, SU 011248, SU-011248, , adalimumab , D2E7 Antibody, Humira, certolizumab, Cimzia, Cimzias, CDP870, CDP870s, CDP 870, CDP 870s, , etanercept , TNF Receptor Type II-IgG Fusion Protein, TNF Receptor Type II IgG Fusion Protein, Enbrel, Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein, Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein, TNFR-Fc Fusion Protein, TNFR Fc Fusion Protein, TNR-001, TNR001, TNR 001, TNT Receptor Fusion Protein, TNTR-Fc, , golimumab , Simponi, , infliximab , MAb cA2, Monoclonal Antibody cA2, Remicade, , anakinra , Interleukin 1 Receptor Antagonist Protein, Urine-Derived IL1 Inhibitor, Urine Derived IL1 Inhibitor, IL1 Febrile Inhibitor, Urine IL-1 Inhibitor, IL-1Ra, Antril, Kineret, Anakinra, , tocilizumab , tocilizumab, atlizumab, Actemra, , rituximab, Rituxan, MabThera, Zytux, Rituximab, Rituximab CD20 Antibody, Mabthera, IDEC-C2B8 Antibody, IDEC C2B8 Antibody, IDECC2B8 Antibody, IDEC-C2B8, IDEC C2B8, IDECC2B8, GP2013, Rituxan, , tofacitinib, tasocitinib, tofacitinib citrate, Xeljanz, CP690550, CP-690550, CP 690550, , durvalumab, durvalumab, Imfinzi, atezolizumab, MPDL3280A, Tecentriq, RG7446, RG-7446, , pemetrexed , MTA, Pemetrexed Disodium, LY 231514, LY231514, LY-231514, Alimta, , rolofylline , rolofylline, KW 3902, KW-3902, MK 7418, MK7418, MK-7418, , tonapofylline , BG 9928, BG-9928, BG9928, BIO 4683, BIO4683, BIO-4683, BIO 5770, BIO5770, BIO-5770, BIO 8170, BIO8170, BIO-8170, BIO 9002, BIO9002, BIO-9002, tonapofylline, BIO 7505, BIO7505, BIO-7505, , serelaxin, canagliflozin, Invokana, , empagliflozin, BI 10773, BI10773, BI-10773, Jardiance, , dapagliflozin, dapagliflozin, forxiga, BMS 512148, BMS512148, BMS-512148, , avelumab , avelumab, MSB0010718C, , crizotinib , Xalkori, PF-02341066, PF02341066, PF 02341066, , finerenone, BAY 94-8862, finerenone, , olaparib, AZD 2281, AZD2281, AZD-2281, AZD221, Lynparza, , niraparib , 2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide, niraparib hydrochloride, MK 4827, MK4827, MK-4827, , talazoparib , BMN 673, , veliparib , 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, 2-(2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, ABT 888, ABT888, ABT-888, , bococizumab, bococizumab, , various diuretics, various ACEI, various beta blockers, alectinib, CH5424802, alectinib, RO5424802, , ceritinib, ceritinib, Zykadia, LDK378, , brigatinib, AP26113, brigatinib, , vandetanib , caprelsa, ZD 6474, ZD6474, ZD-6474, vandetanib, Zactima, , motesanib , imetelstat, motesanib, motesanib diphosphate, AMG 706, AMG706, AMG-706, , aflibercept , aflibercept, VEGF Trap-Eye, VEGF Trap - regeneron, VEGF-Trap, AVE 005, AVE005, AVE-005, Zaltrap, ZIV-aflibercept, AVE 0005, AVE0005, AVE-0005, eylea, , osimertinib , osimertinib, Tagrisso, , rucaparib, rucaparib, AG 014699, AG014699, AG-014699, PF-01367338, , various, cabozantinib , cabozantinib, Cometriq, XL 184, XL184 cpd, XL-184, BMS 907351, BMS907351, BMS-907351, , apitolisib , tivozanib , abemaciclib , abemaciclib, LY2835210, LY2385219, Verzenio, ribociclib , ribociclib, LEE011, , vemurafenib, vemurafenib, Zelboraf, R05185426, RG7204, RG-7204, PLX4032, PLX 4032, , combo dabrafenib + trametinib, durvalumab + tremelimumab , ticilimumab, CP 675, P675 cpd, CP-675, CP-675,206, CP-675206, CP675206, CP 675206,

15 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.